Illumina (NASDAQ:ILMN) Insider Sells $98,400.00 in Stock

Illumina, Inc. (NASDAQ:ILMN) insider Scott Davies sold 615 shares of Illumina stock in a transaction on Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $98,400.00. Following the transaction, the insider owned 21,568 shares in the company, valued at $3,450,880. The trade was a 2.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Performance

NASDAQ:ILMN opened at $170.93 on Thursday. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $25.86 billion, a price-to-earnings ratio of 31.08, a PEG ratio of 2.69 and a beta of 1.50. The firm’s fifty day simple moving average is $136.19 and its 200 day simple moving average is $133.03. Illumina, Inc. has a twelve month low of $81.75 and a twelve month high of $172.49.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.10. The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities research analysts expect that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ILMN. Guggenheim boosted their price objective on shares of Illumina from $170.00 to $180.00 and gave the stock a “buy” rating in a report on Monday. Barclays boosted their price objective on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a report on Friday, May 1st. Wall Street Zen lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Royal Bank Of Canada began coverage on shares of Illumina in a report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price objective on the stock. Finally, Canaccord Genuity Group cut their price objective on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a report on Friday, May 1st. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $138.38.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and reiterated a Buy rating, reflecting optimism about clinical sequencing momentum, consumables pricing, and the company’s pipeline. Article
• Positive Sentiment: Integrated DNA Technologies expanded its collaboration with Illumina, linking xGen FFPE and cfDNA workflows to DRAGEN and Connected Insights, which could deepen Illumina’s role in oncology research and support software adoption. Article
• Positive Sentiment: Recent commentary highlighted Illumina’s better execution, stronger NovaSeq X adoption, and higher full-year 2026 guidance, which has helped extend the stock’s rally. Article
• Neutral Sentiment: Illumina reported small insider sales, including a routine Rule 10b5-1 sale by the chief accounting officer, which is not unusual but adds to scrutiny around insider activity. SEC filing
• Negative Sentiment: Director Keith A. Meister sold a large block of shares in multiple transactions, which could weigh on sentiment despite no direct sign of operational weakness. SEC filing

Hedge Funds Weigh In On Illumina

A number of institutional investors have recently added to or reduced their stakes in the company. Capital World Investors raised its stake in shares of Illumina by 20.0% in the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after purchasing an additional 3,331,542 shares in the last quarter. WCM Investment Management LLC raised its stake in shares of Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares in the last quarter. Invesco Ltd. raised its stake in shares of Illumina by 97.0% in the 4th quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after purchasing an additional 1,352,731 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Illumina by 30.3% in the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after purchasing an additional 1,028,099 shares in the last quarter. Finally, Morgan Stanley raised its stake in shares of Illumina by 66.0% in the 4th quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock valued at $331,710,000 after purchasing an additional 1,005,474 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.